1 / 77

The Breast Course Breast Cancer: Biologicals New Paradigms ---------------------------------

The Breast Course Breast Cancer: Biologicals New Paradigms ---------------------------------. Joseph Ragaz , Director , Oncology Program McGill University Hospital Center May 5 2006. The 1979 – 2000 BrCa Mortality Trends: UK, USA, Canada J.Ragaz, A.Coldman, ASCO 2005.

shiloh
Télécharger la présentation

The Breast Course Breast Cancer: Biologicals New Paradigms ---------------------------------

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Breast CourseBreast Cancer: BiologicalsNew Paradigms--------------------------------- Joseph Ragaz, Director, Oncology Program McGill University Hospital Center May 5 2006

  2. The 1979 – 2000 BrCa Mortality Trends: UK, USA, Canada J.Ragaz, A.Coldman, ASCO 2005

  3. Breast Cancer: Mortality Reduction • Education & screening & downstaging • Endocrine (Tamoxifen & AIs) • Chemotherapy • Radiotherapy • Can we cure more pts? • Molecular Biology

  4. Breast Cancer: Targeted Therapy • Tumor Biology • Biologicals

  5. Genesis of Human Breast Ca:Genes & Genetic markers

  6. Targeted Therapy

  7. Her-2/Neu

  8. The EGFR/HER Family HRG (NRG1) HB-EGF -cel Epi EGF HB-GF Amp TGF NRG1 NRG2 Epi NRG3 Ligand binding domain NRG4 Transmembrane Tyrosine kinase domain Erb-b2 HER2/Neu Erb-b3 HER3 Erb-b4 HER4 erb-b1 EGFR HER1 Mendelsohn and Baselga. Oncogene. 2000;19:6550. Olayioye et al. EMBO J. 2000;19:3159. Prigent and Lemoine. Prog Growth Factor Res. 1992;4:1. Harari and Yarden. Oncogene. 2000;19:6102. Earp et al. Breast Cancer Res Treat. 1995;35:115.

  9. Her2/Neu and Breast Cancer Benign epithelial cells: 20,000 Her2 Receptors Her2+ve BrCa cells:2 million Her2 Receptors Her2/Neuexpression Breast Cancer, overall: 20 – 25% High Grade DCIS: 60 - 70%

  10. HER2 geneAmplification HER2 protein Overexpression Her2/Neu and Breast Cancer Shortened Median Survival HER 2/Neu +ve: 3 yrsHER 2/Neu -ve 6 - 7 yrs Slamon et al, 1987

  11. HER2 Protein Overexpression Associated with Poor Prognosis and Shortened Survival HER2 overexpression: • ER negative status • High S-phase fraction • Positive nodal status • Mutated p53 • High nuclear grade

  12. HER / NEU staining Protein expression IHC: 1+ or 2+ or 3+ Gene Copy: FISH +ve or -ve CISH +ve or -ve

  13. Herceptin: Humanized Anti-HER2 Antibody • Targets HER2 oncoprotein • High affinity (Kd = 0.1 nM) and specificity • 95% human, 5% murine • Decrease potential for immunogenicity • Increase potential for recruiting immune-effector mechanisms

  14. Herceptin:Mode of Action

  15. Herceptin and Chemotherapy • Additive effect • Synergistic effect

  16. Herceptin (Trastuzumab) st. IV : Response only in Her2+ve cases • Slamon et.al. , NEJM, 2001:significant benefit of Herceptin added to Taxol (Paclitaxel) in stage IV disease… • QUESTION: Cost benefit? • Adjuvant studies(NSABP, BCIRG, HERA)…

  17. Adjuvant Trastuzumab Trials NSABP B-31 BCIRG 006 H…x 52 H…x 52 H…x 52 NCCTG 9831 HERA No therapy Standard Chemo Rx H…x 52 H…x 1 years H…x 52 H…x 2 years

  18. NSABP B-31 Control: ACT Arm 1 Arm 2 NCCTG N9831 Arm A Investigational: ACT+H Arm B Arm C = doxorubicin/cyclophosphamide (AC) 60/600 mg/m2 q 3 wk x 4 = paclitaxel (T) 175 mg/m2 q 3 wk x 4 = paclitaxel (T) 80 mg/m2/wk x 12 = trastuzumab (H) 4mg/kg LD + 2 mg/kg/wk x 51

  19. NSABP B-31: Herceptin trial. Her2/Neu +ve cases • ARM 1: AC – Taxol • ARM 2: AC – Taxol + Herceptin x 1 year

  20. Herceptin Adjuvant trials: NSABP B-31 & NCCTG N9831, NEJM, Oct 2005 ARMS: AC-T AC-T+ H* HR p ------------------------------------------------------------------ • 4 DFS%:85% 67% 0.48p<.00001 • 4 OS%:0.670.015 • CHF: 1%4%* • < 50 vs >50 years: (2 vs 5.5%) , CHF: most reversible * H=Herceptin

  21. Impact of Adjuvant Herceptin, DFS, NSABP-NCTCG analyses, NEJM Oct 2005 ACTaxol - Herceptin 85% 87% ACT % 75% AC-Taxol alone 67% HR=0.48 2P=<0.000001 Years From Randomization

  22. Targeting “Targeted Therapy” • Can we identify subsets who will benefit (from Herceptin) much more, and those who will benefit much less…

  23. HerceptinSensitivity Resistance(PTEN expression) (PTEN loss)

  24. Herceptin Response vs PTEN RR% to Herceptin • All pts (Her2+ve) N: 47 35-50% ------------------------------------------------------------------- • High PTEN (30 pts): 65% • Loss of PTEN: (17 pts): 10% p = <0.01 * Nagata Y, et.al., Cancer Cell, Aug. 2004, 6: 117-127

  25. Role of c-Myc

  26. NSABP B 31: Herceptin subanalysis according to cMyc, S. Paik et.al. • 1736 Her2+ve pts had cMyc analysis • 432 (30%) were Her2 + cMyc +ve

  27. NSABP B-31, according to cMyc: all are Her2+ve 432 pts ======================== • Recurrences: RR ALL: 0.48 ------------------------------------------- cMyc-: 0.63 cMyc+: 0.23 ------------------------------------------

  28. NSABP B-31, according to cMyc: all are Her2+ve cMyc-cMyc+ p 1,078 432 ======================== • Deaths:0.99 0.36 0.037

  29. San Antonio 2005 • DCIS and Her2/Neu expression

  30. Adjuvant Trastuzumab Trials NSABP B-31 BCIRG 006 H…x 52 H…x 52 H…x 52 NCCTG 9831 HERA No therapy Standard Chemo Rx H…x 52 H…x 1 years H…x 52 H…x 2 years

  31. BCIRG 006: Adj. 4 x Docetaxel 100 mg/m2 4 x AC60/600 mg/m2 ACTax Her2+ (Central FISH) N+ or high riskN- 4 x Docetaxel 100 mg/m2 4 x AC60/600 mg/m2 ACTax Herceptin 1 Year Trastuzumab 6 xDocetaxel and Carboplatin 75 mg/m2 AUC 6 N=3,222 TaxCarbo Herceptin Stratified by Nodes and Hormonal Receptor Status 1 Year Trastuzumab Slamon D., SABCS 2005

  32. Disease Free Survival 1.0 93% 0.9 91% 86% 84% 86% 80% 80% 0.8 77% % Disease Free 73% 0.7 Patients Events 0.6 1073 147 AC->T No Herceptin HR (AC->TH vs AC->T) = 0.49 [0.37;0.65] P<0.0001 1074 77 AC->TH 1075 98 TCH HR (TCH vs AC->T) = 0.61 [0.47;0.79] P=0.0002 0.5 0 1 2 3 4 5 Year from randomization

  33. CARDIAC TOXICITY

  34. Clinically significant cardiac eventsas per independent review panel P = 0.016 P = 0.11 P = 0.54

  35. Normal Amplified Deletion TOPO II region Topo II NonCo-Amplified Co-Amplified 744 pts (35%) HER2 and TOPO II in BCIRG 006 2120 of 3222 patients analyzed 17 q 12 17 q 21.1 17 q 21.2 HER2 Core region N=2120 1285 pts (60%) 91 pts (4%)

  36. DFS according to Topo II 1.0 0.9 Co-Amplified % Disease Free 0.8 Non Co-amplified 0.7 Patients Events Topo II 744 57 Co-Amplified Logrank P<0.001 1376 191 Non Co-amplified 0.6 0.5 1 2 3 4 5 0 Year from randomization

  37. Topo II and Human BrCa • Topo II is the target for anthracyclines • Topo II is associated with inferior outcome

  38. DFS according to Topo II: Topo II +ve 1.0 AC->TH AC->T 0.8 % Disease Free TCH Patients Events Treatment AC->T 227 23 Logrank P= 0.24 265 13 AC->TH 252 21 TCH 0.6 0.5 0 6 12 18 24 30 36 42 48 54 Months

  39. DFS according to Topo II: Topo II - ve 1.0 0.8 % Disease Free AC->TH TCH Patients Events Treatment 0.6 458 92 AC->T 472 45 AC->TH Logrank P= <0.001 AC->T 446 54 TCH 0.0 0 6 12 18 24 30 36 42 48 54 Months

  40. Conclusion: Outcome according to Topo II • Among Topo II+ve (35% case): Herceptin + Carbo Tax is inferior to Herceptin + Anththracyclines • Among Topo II-ve (65% cases): Herceptin + Carbo Tax is same as Herceptin + Anththracyclines

  41. Might 9 weeks of Herceptin be enough?

  42. Might 9 weeks of Herceptin be enough?H. Joensuu, et.al., Helsinki, Abstr. #2 1010 stage I-II BrCa, T>2 cm, Her2+ve 1st Randomization: • ARM 1: Docetaxel 100 mg/m2 x 3 wks x 3 over 9 wks followed by CEF x 3 (C600E60F600) • ARM 2: Navelbine 25 mg/m2 weekly x 8 over 9 weeks followed by CEF x 3 (C600E60F600) 2nd Randomization (232 CISH +ve pts): • ARM1: Herceptin weekly x 9 weeks • ARM 2: No Herceptin

  43. Might 9 weeks of Herceptin be enough?H. Joensuu, et.al., Helsinki, Abstr. #2 Herceptin vs not HR p ======================= • Any recurrence: 0.46* 0.008 • Distant DFS: 0.43 0.008 • Overall Survival: 0.43* 0.08 * 54% reduction of recurrences due to Herceptin * 57% reduction of mortality due to Herceptin

  44. 10.Cost & Benefit Of Adjuvant Herceptin / 1000 newly diagnosed (15% of all pts. treated); RR=0.5Underlying recurrence rate: 60%.

  45. 12. Cost Benefit of Adjuvant Herceptin: Dollars spent vs Recurrences avoided(15% of all pts. treated; underlying recurrence rate: 60%)

  46. 13. Cost Benefit of Adjuvant Herceptin: therapy according to the “PTEN” statusTreated are only Her2+ve PTEN cMyc +ve (9% of newly 1,000 dg)

  47. Protein: Immunohistochemistry (IHC): simpler, cheaper than FISH, 1st screening test Gene: Fluorescence in situ Hybridization ============================================================ IHC: –ve, 1+:No Herceptin: IHC 2+ :Possible Herceptin: FISH retesting: 20-30% are FISH +ve IHC 3+:Herceptin indicated (n.b. FISH retesting, 10-15% are FISH –ve) The 2006 guidelines: FISH required for all IHC 2+ and 3+ Elligibility for adjuvant Herceptin: Detemination of Her2/Neu status

  48. Tissue Micro-Arrays: • Validation of new genes & proteins ... • Stains of archival (paraffin embedded) tumor samples: • 300 pts / 1 plattform / long f/up…. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine 4:844-7, 1998

  49. the red dots are her2/neu gene copies. greenish small dots are the cept 17/ chr D.Huntsman, L.Brown, BCCA Her2/Neu: FISH , presently “Gold Standard”….

  50. Her-2/Neu testing: FISH ADVANTAGES: • Close to 100% specific • 96.5% sensitive • Low inter-laboratory variation DIS-ADVANTAGES: • High Cost and specialised equipment (Florescent microscopy) • Limited availability to community

More Related